



| カタログ番号 | HB185076 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG1-kappa |
| クローンID | BI 836858 |
| 生物学的活性 | BI-836858 (10 ug/mL; 30 min) mediates specific ADCC activity against primary AML blasts [1]. BI-836858 (2 ug/mL; 4 h) mediates NK cell-dependent ADCC activity against CD33-positive HL60 cells [2]. BI-836858 (2 ug/mL; 48 h) blocks the CD33-mediated inhibitory signaling pathway in MDS bone marrow cells and reduces the expression of IL-10 and TGFβ [2]. BI-836858 (2 ug/mL) specifically blocks CD33 (S100A9)-mediated ROS production in U937 cells, healthy PBMCs, and primary MDS BM HSPCs [2]. BI-836858 (2 ug/mL; 14 days) restores the hematopoietic colony-forming capacity in ex vivo cultures of primary MDS bone marrow specimens [2]. |
| 発現システム | Mammalian cells |
| ターゲット | Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3 |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% purity as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | P20138 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | BI-836858, BI836858, BI836858 |
| 背景 | Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg). 1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343 2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212 3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323 4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872 5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109 6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905 7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955 8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798 |
| 参考文献 | 1. Gopalakrishnan B, et al. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 2018;9(11):9706-9713. Published 2018 Jan 3. [HB185076] 2. Eksioglu EA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172-2180. [HB185076] |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SDS-PAGE for Research Grade Anti-Human CD33 (BI 836858)

Detects recombinant human CD33 (Catalog No: HB185011) in indirect ELISA




+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206

中文
English
한국어
日本語
Español
Français
Русский